Relationship About Pregnancy Health and Offspring Developmental &Behavioral Outcomes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age3-72
SponsorChen Li

About this trial

This topic puts forward a hypothesis: genetic and environmental factors such as major depressive disorder during pregnancy, nutritional status of vitamin A, D, E, and folic acid, intestinal microecology, and bisphenol A exposure, may affect the cognitive development level of the offspring through the genetic correlation with attention deficit hyperactivity disorder, developmental delay/intellectual disability, and major depressive disorder, allelic heterogeneity and pleiotropy of ITIH3 mediated by SNP and CACNB2, neurotransmitters like dopamine, and metabolic pathways, thereby increasing the risk of attention deficit hyperactivity disorder and developmental delay/intellectual disability prevalence on offspring.

This topic planning from allelic heterogeneity and pleiotropy of attention deficit hyperactivity disorder and major depressive disorder mediated by SNP, neurotransmitters like dopamine, and metabolic pathways, explores deeply the influences on children's development level and the risk of common neurological disorder caused by genetic and environmental factors during pregnancy, looking for reasonable prevention, early diagnosis of biomarkers and therapeutic targets, in order to provide data support for further improvement and revision of national mother and infant healthcare policy .

Eligibility criteria

Qualifiers

Inclusion criteria for pregnant women: Aged 20~49;

no cognitive impairment, able to complete the scale test;

Hamilton Depression Scale (HAMD questionnaire) is normal (HAMD score <8 points) or mild to moderate positive (HAMD questionnaire score: 8~35 points);

Participants are asked for their own written informed content for the study;

Disqualifiers

Patients receiving anti-depression therapy during the first 6 months of gestation or during pregnancy;

Patients with severe depression with scores of no less than 35 points in the HAMD questionnaire;

Patients with other mental disorders;

Patients with neurological diseases;

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

3,000 Participants
are grouped into 4 trial groups

Sponsors and collaborators

Chen Li

Lead sponsor

Children's Hospital of Chongqing Medical University

Sponsor institution